Norfloxacin + tinidazole

Full Generic Medicine Info
Dosage/Direction for Use

Diarrhoea and dysentery of amoebic, bacterial or mixed origins
Adult: Per tablet contains norfloxacin 400 mg and tinidazole 600 mg: 1 tablet bid for 5 days.
Hypersensitivity, neurological disorders including convulsions, blood dyscrasias, children. Pregnancy and lactation.
Special Precautions
Moderate renal impairment, history of or susceptibility to seizures, alcohol intake. Ensure adequate hydration and urine output.
Adverse Reactions
Nausea, vomiting, heartburn, metallic taste, headache, dizziness, depression, insomnia, rash, dry mouth, fever, arthralgia. Rarely eosinophilia, bone marrow depression.
Potentially Fatal: Rarely hypersensitivity reactions, facial and laryngeal oedema, hypotension, bronchospasm.
Drug Interactions
Antacids reduce absorption of norfloxacin from gut. Probenecid reduces urinary excretion of norfloxacin.
Potentially Fatal: Increased levels of theophylline and ciclosporin, warfarin effects potentiated, disulfiram-like reactions with alcohol.
Food Interaction
Reduced absorption of norfloxacin esp with milk or yogurt.
Tinidazole is active against protozoa and anaerobic bacterial infections against which norfloxacin is inactive. The combination of norfloxacin and tinidazole has an extended range of antimicrobial spectrum and is effective in mixed gut infections, diarrhoeas and dysentery.
ATC Classification
P01AB02 - tinidazole ; Belongs to the class of nitroimidazole derivatives antiprotozoals. Used in the treatment amoebiasis and other protozoal diseases.
J01MA06 - norfloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.
J01XD02 - tinidazole ; Belongs to the class of imidazole derivative antibacterials. Used in the systemic treatment of infections.
S01AE02 - norfloxacin ; Belongs to the class of quinolone antiinfectives. Used in the treatment of eye infections.
Disclaimer: This information is independently developed by CIMS based on norfloxacin + tinidazole from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in